SCHEMBL2086359

SCHEMBL2086359

CCOc1ccc(CN)nc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 3/20 0.42
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 3/20 0.37
MAPK1 P28482 2/20 0.37
KDM1A O60341 2/20 0.36
ALDH1A1 P00352 3/20 0.36
TLR8 Q9NR97 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2085446 0.87 DPP4 (0.36) AOC3HSD17B10MAPK1ALDH1A1L3MBTL1
SCHEMBL2085198 0.82 CCR1 (0.39) KDM4EHSD17B10MAPK1KDM1AALDH1A1
SCHEMBL2085154 0.76 KDM4E (0.43) KDM4EHSD17B10MAPK1KDM1AL3MBTL1
SCHEMBL9140861 0.74 KDM4E (0.39) KDM4EHSD17B10MAPK1KDM1AALDH1A1
SCHEMBL7960097 0.74 KDM4E (0.41) AOC3KDM4EHSD17B10MAPK1ALDH1A1
Hydrochloric Acid SCHEMBL1871955 0.72 KDM4E (0.44) AOC3KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL21060577 0.71 KMT2A (0.43) KDM4EHSD17B10MAPK1ALDH1A1L3MBTL1
SCHEMBL29561785 0.71 KMT2A (0.43) KDM4EHSD17B10MAPK1ALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL30816953 0.69
SCHEMBL17527769 0.69 L3MBTL1 (0.48) KDM4EHSD17B10MAPK1KDM1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863269-B2 protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
US-7863269-B2 protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
US-7863269-B2 protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
EP-2054412-B1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI AVENTIS (FR) 2009-12-02 EP disclosed
EP-2054412-B1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI AVENTIS (FR) 2009-12-02 EP disclosed
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-07-30 US disclosed
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-07-30 US disclosed
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-07-30 US disclosed
EP-2054412-A2 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY Sanofi-Aventis (FR) 2009-05-06 EP disclosed
WO-2008014888-A2 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2008-02-07 WO disclosed
WO-2008014888-A2 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY F2R, TFPI, F2RL1 AOC3 833/4885KDM4E 4314/4885HSD17B10 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.